Key facts
- Cellvie’s last known valuation is $14.0M (Jan 2021).
- It has raised $15.5M; the latest was Later Stage VC ($5.0M) in Sep 2025.
- Notable investors include MedTech Innovator, Innosuisse, Harvard University, Beiersdorf, Beiersdorf. — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Cellvie
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellvie are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellvie
Developer of mitochondria-based therapeutic technology intended to restore cellular bioenergetics and improve organ function. The company utilizes isolated mitochondria derived from donor cells to repair damaged or energy-depleted cells through infusion, enabling the healthcare providers to address conditions linked to mitochondrial dysfunction.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2018
- Employees
- 10
- Website
- cellvie.bio/
- Ownership
- Privately Held (backing)
Cellvie doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellvie shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellvie in its N-PORT filings yet. We sweep new filings monthly.